Our findings are in contrast to those observed in previous studies where higher PRL levels were found to associate with greater risk of incident diabetes [45], and treatment to reduce PRL levels with a dopamine agonist (Bromocriptine) improves glycaemic control. Here, PRL is linked to diabetes mellitus.